

PATHOLOGY GRAND ROUNDS



Jinru Shia, M.D.

Attending Pathologist
Memorial Hospital for Cancer and Allied Diseases
Member Memorial Sloan Kettering Cancer Center
Professor of Pathology and Lab Medicine
Weill Cornell Medical College

“Decoding Lynch Syndrome and MSI: The Pathologist’s Role Constantly Evolving and Consistently Essential”

Thursday, November 14, 2019

12:30 p.m.

Fitkin Amphitheater – LMP 1094

Host: Xuchen Zhang, M.D., Ph.D. & Manju Prasad, M.D.



There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

NEEDS ASSESSMENT

Tumor DNA microsatellite instability (MSI) first discovered in colorectal carcinoma in 1993 has evolved into an important marker for 1) detection of Lynch Syndrome, and 2) Prediction of response to anti-PD-1 immunotherapy. The significance of these 2 major applications was highlighted by the 2016 NCCN en-

dorsement of universal MSI/MMRd testing in patients with colorectal carcinoma, and the 2017 FDA first ever tissue-agnostic approval for anti-PD-1 therapy across unresectable or metastatic MSI/MMRd solid tumors respectively. As of now, in the clinical application of MSI, and MSIs/MMRds are treated equally. This premise however, has been challenged by the emerging data that are revealing remarkable genetic and phenotypical diversities in tumors with MSI/MMRds. This discussion reviews some of the recent progress, and emphasizes that the important role the pathologists have played in the development of MSI thus far will continue on as the field continues to advance.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to achieve a better understanding of:

- The current status of MMRd tumors;
- The genetic & phenotypical diversities of MMRd tumors;
- The pathologist's role evaluating MMRds.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Speaker Name: Jinru Shia, MD - NONE
Course Directors: Manju Prasad, MD - NONE

Kurt Schalper, MD, PhD - NONE

Gopal Pallavi, MD, PhD - NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.